Literature DB >> 3038802

Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung.

L R Holsti, K Mattson, A Niiranen, C G Standertskiöld-Nordenstam, S Stenman, A Sovijärvi, K Cantell.   

Abstract

The effects on lung tissue and tumor of natural human alpha interferon (IFN) and radiotherapy were investigated in a multimodality treatment program for selected patients with small cell carcinoma of the lung (SCLC). Interferon was given first as a single agent, then concomitantly with radiotherapy to 12 previously untreated patients with limited disease. At disease progression outside the chest, interferon was discontinued and combination chemotherapy was initiated. In the first series, 7 patients received a high interferon induction dose (800 X 10(6) IU i.v. over 5 days) followed by low-dose maintenance therapy (6 X 10(6) IU i.m. TIW), median total dose 1380 X 10(6) IU (range 794-2074). At local progression, split-course radiotherapy, 55 Gy/20 F/7 wk, was added to interferon therapy. In the second series, 5 patients received low-dose interferon from the start (6 X 10(6) IU i.m. daily) combined with twice-a-day fractionated radiotherapy 44 Gy/40 F/4 wk. Median total dose of interferon in this series was 698 X 10(6) IU (range 354-828). Tumor response and normal tissue reactions were evaluated by monthly chest X rays, 3-monthly CT scans, restaging bronchoscopies and by serial respiratory function tests. Autopsy specimens from both lungs within and outside the radiation field were systematically evaluated when available. After the completion of radiotherapy, there were 4/7 CR in the high-dose IFN group compared to 3/5 CR in the low-dose IFN group. Rapid shrinkage of huge tumor masses was observed. At 2 months post radiotherapy radiological grade III fibrosis occurred in 4/7 patients in the high-dose and 1/5 patients in the low-dose group. Lung function studies showed a significant decrease in diffusing capacity and in lung volumes. Seven patients died within 12 months from start of interferon treatment, one of them from treatment complication. At autopsy the tumor area was in most cases replaced by severe fibrosis. Outside the radiation field lung fibrosis was mild. Our results suggest enhancement of radiation effect by interferon with a possible dose and/or schedule dependence of interferon and radiotherapy and call for more clinical studies of IFN and radiotherapy in combination.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038802     DOI: 10.1016/0360-3016(87)90189-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

1.  Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.

Authors:  Jian-Hua Ma; Emilia Patrut; Jan Schmidt; Hanns-Peter Knaebel; Markus W Büchler; Angela Märten
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

2.  Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.

Authors:  V J Picozzi; R A Abrams; P A Decker; W Traverso; E M O'Reilly; E Greeno; R C Martin; L S Wilfong; M L Rothenberg; M C Posner; P W T Pisters
Journal:  Ann Oncol       Date:  2010-07-29       Impact factor: 32.976

Review 3.  Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer.

Authors:  Flavio G Rocha
Journal:  Ann Surg Oncol       Date:  2021-01-01       Impact factor: 5.344

4.  Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer.

Authors:  J J Beitler; S Wadler; H Haynes; S Fell; A Rozenblit; E Wolf; B A Levine
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

5.  Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.

Authors:  Christopher J LaRocca; Joohee Han; Tatyana Gavrikova; Leonard Armstrong; Amanda R Oliveira; Ryan Shanley; Selwyn M Vickers; Masato Yamamoto; Julia Davydova
Journal:  Surgery       Date:  2015-02-27       Impact factor: 3.982

Review 6.  The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer

Authors:  Mizuho Sato-Dahlman; Masato Yamamoto
Journal:  Curr Cancer Drug Targets       Date:  2018       Impact factor: 3.428

7.  [Treatment of stage IIIB loco-regionally advanced non-small-cell bronchial carcinomas with radiation and interferon-beta. Preliminary results of a phase II study].

Authors:  J Bund; K Eberhardt; W Hartmann; H J Habermalz
Journal:  Strahlenther Onkol       Date:  1998-06       Impact factor: 3.621

8.  Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.

Authors:  E E Vokes; D J Haraf; P C Hoffman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.

Authors:  E E Vokes; D J Haraf; L C Drinkard; P C Hoffman; M K Ferguson; N J Vogelzang; S Watson; N J Lane; H M Golomb
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.

Authors:  Angela Märten; Jan Schmidt; Jennifer Ose; Sabine Harig; Ulrich Abel; Marc W Münter; Dirk Jäger; Helmut Friess; Julia Mayerle; Guido Adler; Thomas Seufferlein; Thomas Gress; Roland Schmid; Markus W Büchler
Journal:  BMC Cancer       Date:  2009-05-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.